Better Buy: Eli Lilly vs. Pfizer

Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE) are two of several pharma giants in the race to combat COVID-19. Eli Lilly is currently evaluating three potential therapies for the disease in clinical trials, while Pfizer has kicked off a phase 3 study for its lead COVID-19 vaccine candidate. So far this year, Eli Lilly has outperformed Pfizer in the stock market.

While Eli Lilly is up by almost 13% year to date, Pfizer is down by over 3% during the same period. The S&P 500 has recovered its losses and gained 6.2% on the year. Both of these stocks have exciting growth prospects. But which one will outperform the other moving forward? Let's dig into their respective businesses and decide which is the better buy today. 

Continue reading

Source Fool.com